Embryonation and infectivity of Ascaris suum eggs isolated from worms expelled by pigs treated with albendazole , pyrantel pamoate, ivermectin or piperazine dihydrochloride.
The effect of anthelmintic treatment of pigs on the embryonation and infectivity of Ascaris suum eggs isolated from expelled worms was investigated. Four groups of two naturally infected pigs were dosed with albendazole, pyrantel pamoate, ivermectin or piperazine dihydrochloride, respectively. Following worm expulsion, the eggs were removed from the uteri of female worms and embryonated in sulphuric acid. The infectivity of the embryonated eggs was tested through mouse inoculation. Egg development appeared normal in cultures from worms of the piperazine. pyrantel and ivermectin treated groups. In the albendazole cultures, egg development was largely arrested at the one-cell stage (81%). Where development occurred, irregular cell division was observed and only 7% of the eggs in the culture developed into fullgrown larvae. Following mouse inoculation with 2500 embryonated eggs, significantly lower lung larval counts on day 8 post inoculation (p.i.) were observed for mice in the piperazine and pyrantel treated groups (P < 0.01) compared to untreated controls. The larvae that developed in the eggs from ivermectin and albendazole treated groups appeared fully infective for mice. It was concluded that ovicidal activity of albendazole in vivo inhibits subsequent A. suum egg development in vitro; albendazole is, therefore, not suitable to obtain worms for egg embryonation to produce experimental inoculums. The anthelmintic treatment of pigs with ivermectin had only a limited effect on both embryonation and infectivity of A. suum eggs isolated from expelled worms.
Boes
J
J
Danish Centre for Experimental Parasitology, Department of Veterinary Microbiology, The Royal Veterinary and Agricultural University, Frederiksberg. jbo@kvl.dk
Eriksen
L
L
Nansen
P
P
D015766:Albendazole / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D000969:Antinematodal Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001196:Ascariasis / Q000188:drug therapy / Q000662:veterinary*; D017165:Ascaris suum / Q000187:drug effects* / Q000502:physiology; D004627:Embryonic Induction / Q000187:drug effects / Q000502:physiology; D005243:Feces / Q000469:parasitology; D005260:Female; D007559:Ivermectin / Q000494:pharmacology / Q000627:therapeutic use; D008168:Lung / Q000469:parasitology; D051379:Mice; D008807:Mice, Inbred BALB C; D010063:Ovum / Q000187:drug effects / Q000276:immunology / Q000502:physiology; D010270:Parasite Egg Count / Q000662:veterinary; D000077489:Piperazine; D010879:Piperazines / Q000494:pharmacology / Q000627:therapeutic use; D011716:Pyrantel Pamoate / Q000494:pharmacology / Q000627:therapeutic use; D013552:Swine; D013553:Swine Diseases / Q000188:drug therapy* / Q000469:parasitology
D000969:Antinematodal Agents; D010879:Piperazines; D000077489:Piperazine; D007559:Ivermectin; D011716:Pyrantel Pamoate; D015766:Albendazole